Bladder Cancer
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC.
August 22, 2024
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
August 21, 2024
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study.
August 20, 2024
Optimal Management for Primary High Grade Ta Bladder Cancer: Role of re-staging TURBT and Intravesical Adjuvant Therapy.
August 20, 2024
Compressed sensing 3D T2WI radiomics model: improving diagnostic performance in muscle invasion of bladder cancer.
August 20, 2024
Economic Impact of Bladder Cancer in the USA.
August 19, 2024
Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer.
August 16, 2024
Predictors of Early Continence After Single-port Transvesical Robot-assisted Radical Prostatectomy.
August 16, 2024
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
August 15, 2024
Impact of diabetes mellitus on oncologic outcomes in patients receiving robot-assisted radical cystectomy for bladder cancer.
August 15, 2024
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.
August 15, 2024